Skip to main content

Table 2 Factors associated with lost to follow-up over time among ART patients, N = 5901

From: A clinical decision support system is associated with reduced loss to follow-up among patients receiving HIV treatment in Kenya: a cluster randomized trial

Characteristic Unadjusted odds ratios Adjusted odds ratios
OR (95% CI) P value Global p value OR (95% CI) P value Global p value
Site status       
Control intervention 0.70 (0.65–0.76) < .001 < .001 0.70 (0.65–0.77) < .001 < .001
Age group, years       
< 10 years       
10–19 years 1.41 (1.13–1.77) 0.003 0.127 1.2 (0.95–1.5) 0.126 0.187
20–29 years 0.88 (0.76–1.02) 0.087   0.88 (0.75–1.04) 0.129  
30–39 years 0.94 (0.82–1.08) 0.393   0.94 (0.8–1.12) 0.499  
40–49 years 1.14 (0.98–1.33) 0.093   1.01 (0.85–1.21) 0.872  
50–59 years 0.92 (0.77–1.1) 0.376   0.9 (0.74–1.11) 0.335  
60 + years 1.12 (0.86–1.46) 0.4   1.11 (0.83–1.47) 0.482  
Sex       
Male       
Female 1.01 (0.94–1.09) 0.713 0.713 0.95 (0.87–1.03) 0.193 0.193
Marital status       
Divorced/Separated       
Married 1.55 (1.25–1.92) < .001 < .001 1.34 (1.11–1.61) 0.002 < .001
Single 2.97 (2.37–3.72) < .001   1.39 (1.13–1.72) 0.002  
Widow 1.56 (1.25–1.94) < .001   1.43 (1.17–1.74) 0.001  
CD4 category       
< 200       
200–350 1.49 (1.36–1.65)  < .001 0.678    
350–500 1.07 (0.82–1.39) 0.633     
≥ 500 0.98 (0.75–1.28) 0.853     
WHO stage       
WHO IV       
WHO I 2.75 (2.13–3.55) < .001 < .001 1.24 (0.98–1.58) 0.076 0.026
WHO II 1.71 (1.33–2.2) < .001   1.36 (1.08–1.72) 0.01  
WHO III 1.35 (1.05–1.73) 0.019   1.27 (1.01–1.6) 0.044  
First line regimen       
Other       
Efavirenz 1.90 (1.09–3.32) 0.024 < .001 1.83 (1.04–3.21) 0.036 < .001
Nevirapine 3.18 (1.84–5.51)  < .001   2.82 (1.62–4.91) < .001